Tag: AI platform

Bayer Steps Back from Blackford

Posted on by Brian Casey

Pharmaceutical giant Bayer said it plans to deprioritize its investment in AI platform company Blackford Analysis as part of a general move away from the platform business. Bayer is also winding down its investment in Calantic Digital Solutions, the digital platform company it formed in 2022. 

The move is a stunning turnaround for Blackford, which was founded in 2010 and was the first and perhaps most prominent of the digital AI platform companies. 

  • Bayer acquired Blackford in 2023, and operated it in parallel with Calantic, which also offered AI solutions in the platform format. 

Platform AI companies have a simple value proposition: rather than buy AI algorithms from multiple individual developers, hospitals and imaging facilities contract with a single platform company and pick and choose the solutions they need.

  • It’s a great idea, but platform providers face the same challenges as algorithm developers due to slower-than-expected AI clinical adoption. 

Bayer’s move was confirmed by company representatives, who noted that personnel will be maintained to support the Blackford AI platform and fulfill existing contractual commitments. 

  • “Bayer has made the decision to deprioritize its digital platform business, which includes Blackford, and will discontinue offerings and services. Resources will be reinvested into growth areas that support healthcare institutions around the world, in alignment with customer needs,” the representative said. 

And in a letter to customers obtained by The Imaging Wire, Blackford confirmed Bayer’s decision, stating that Blackford’s core team will remain in place led by COO James Holroyd during the transition. 

  • The company also said it would “discuss and facilitate opportunities to move existing Blackford contracts into direct deals with AI vendors, or alternate platform providers.”

Bayer’s withdrawal from the digital platform space includes the Calantic business, which Bayer formed three years ago to offer internally developed AI tools.

  • At the time, industry experts postulated that contrast agent companies had an inside track for radiology AI thanks to their contracts to supply consumables to customers – a theory that in retrospect hasn’t borne fruit.

Speculation about Blackford’s fate burst into the public eye late last week with a detailed LinkedIn post by healthcare recruiter Jay Gurney, who explained that while Blackford has been successful – and is sitting on a “monster pipeline” of hospital deals – it’s simply not a great fit for a pharmaceutical company. 

  • Despite Bayer’s withdrawal, Blackford could make a good acquisition candidate for a company without a strong AI portfolio that wants to quickly boost its position. 

The Takeaway

Bayer’s announcement that it’s winding down its Blackford and Calantic investments is sure to send shockwaves through the radiology AI industry, which is already struggling with slow clinical adoption and declining venture capital investment. The question is whether a white knight will ride to Blackford’s rescue.

Arterys and Tempus’ Precision Merger

Posted on by Jake Fishman

Arterys was just acquired by precision medicine AI powerhouse Tempus Labs, marking perhaps the biggest acquisition in the history of imaging AI, and highlighting the segment’s continued shift beyond traditional radiology use cases. 

Arterys has become one of imaging’s AI platform and cardiac MRI 4D flow leaders, leveraging its 12 years of work and $70M in funding to build out a large team of imaging/AI experts, a solid customer base, and an attractive intellectual property portfolio (AI models, cloud viewer, and a unique multi-vendor platform).

Tempus Labs might not be a household name among Imaging Wire readers, but they’ve become a giant in the precision medicine AI space, using $1.1B in VC funding and the “largest library of clinical & molecular data” to develop a range of precision medicine and treatment discovery / development / personalization capabilities.

It appears that Arterys will continue to operate its core radiology AI business (with far more financial support), while supporting the imaging side of Tempus’s products and strategy.

This acquisition might not be as unprecedented as some think. We’ve seen imaging AI assume a central role within a number of next-generation drug discovery/development companies, including Owkin and nference (who recently acquired imaging AI startup Predible), while imaging AI companies like Quibim are targeting both clinical use and pharma/life sciences applications.

Of course, many will point out how this acquisition continues 2022’s AI shakeup, which brought at least five other AI acquisitions (Aidence & Quantib by RadNet; Nines by Sirona, MedoAI by Exo, Predible by nference) and two strategic pivots (MaxQ AI & Kheiron). Although these acquisitions weren’t positive signs for the AI segment, they revealed that imaging AI startups are attractive to a far more diverse range of companies than many could have imagined back in 2021 (including pharma and life sciences).

The Takeaway

Arterys just transitioned from being an independently-held leader of the (promising but challenged) diagnostic imaging AI segment to being a key part of one of the hottest companies in healthcare AI, all while managing to keep its radiology business intact. That might not be the exit that Arterys’ founders envisioned, but in many ways it’s an ideal second chapter.

Arterys’ Platform Expansion

Posted on by Jake Fishman

At a time when many major AI companies are trying to become AI platform companies, Arterys announced a trio of 3rd party AI alliances that showed how a mature AI platform might work.

Arterys Expands Neuro AI – Arterys launched neuroradiology AI alliances with Combinostics and Cercare Medical, expanding Arterys’ already-comprehensive Neuro AI suite (also includes MRI brain tumor diagnostics, CT stroke & ICH detection, 2D/4D Flow brain MRI). Combinostics’ cNeuro cMRI supports multiple neurological disorder assessments (specifically dementia and multiple sclerosis), while Cercare Perfusion automates brain CT and MRI perfusion map generation and stoke treatment decision making. 

Arterys Adds Breast AI – Arterys launched a global distribution agreement with iCAD, making iCAD’s full suite of breast health solutions available in Arterys’ new Breast AI suite. iCAD’s portfolio is certainly broad enough to deserve its own “suite,” ranging from 2D and 3D mammography detection, personalized risk screening and decision support, and density assessments. The Arterys Breast AI suite also makes iCAD available as a cloud-based SaaS solution for the first time (previously only on-premise).

Arterys Platform Impact – Arterys’ integration of multiple complementary AI tools within curated AI Suites is unique and makes a lot of sense. It seems to be far more helpful to provide neurorads with integrated access to a suite of neuro AI tools, than to provide them with one or two tools for every subspecialty.

The Takeaway – Arterys’ new alliances reveal a far more subspecialist-targeted approach than we usually see from AI platforms or marketplaces. It also shows that Arterys is committed to its vendor neutral strategy, effectively doubling its number of active AI partners (previously: Imaging Biometrics & Avicenna.AI in Neuro suite, MILVUE in Chest MSK Suite), while highlighting the value of its cloud-native structure for integrating new partners within the same user interface.

Aidoc & Riverain’s Platform Partnership

Posted on by Jake Fishman

Aidoc and Riverain Technologies announced a new partnership that will make Riverain’s ClearRead CT and ClearRead Xray solutions available on the Aidoc platform, while advancing the companies’ respective platform strategies. 

The Chest AI Package – In addition to offering Riverain’s AI tools individually, Aidoc will provide them as part of an ‘integrated chest AI package’ that also includes Aidoc’s modules for PE, incidental PE, and rib fractures. 

Riverain’s Platform Push – Riverain has amassed a solid network of AI marketplace and OEM partners over the years, and it now appears to be expanding its channel to complementary AI vendors. Riverain’s new Aidoc alliance comes just a few weeks after a similar partnership with Volpara that combines ClearRead CT with the Volpara Lung platform.

Aidoc’s Platform Portfolio – After years of building out its homegrown AI portfolio (7 products) and customer base (600 health centers), Aidoc is evolving into an AI platform company. Over the last year, Aidoc has assembled a solid AI portfolio that combines its own triage products with solutions that it doesn’t offer (Imbio, Icometrix, Subtle Medical, Riverain), allowing its clients to expand their AI stack without overhauling their infrastructure with each new tool.

The Takeaway – We’re at an interesting time in the AI space with a small handful of diversified AI players (e.g. Aidoc, Qure.ai), a group of focused category leaders (e.g. Riverain w/ thoracic, ScreenPoint w/ mammography), and an AI customer base that would prefer not to support multiple AI infrastructures. Although marketplaces also solve this problem, it’s easy to see how complementary vendor partnerships like these could play a growing role in how AI is delivered going forward.

Get every issue of The Imaging Wire, delivered right to your inbox.